High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer

Bone Marrow Transplantation

Volumn 22, Issue 7, 1998, Pages 651-659

  Holmberg, L A ^a,b   Demirer, T ^a   Rowley, S ^a,b   Buckner, C D ^a,b,c   Goodman, G ^a   Maziarz, R ^a   Klarnet, J ^a   Zuckerman, N ^a   Harrer, G ^a   McCloskey, R ^a   Gersh, R ^a   Goldberg, R ^a   Nichols, W ^a   Jacobs, A ^a   Weiden, P ^a   Montgomery, P ^a   Rivkin, S ^a   Appelbaum, F R ^a,b   Bensinger, W I ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Response Oncology Inc   (United States)

Author keywords

Busulfan; High dose chemotherapy; Melphalan; Ovarian cancer; PBSC; Thiotepa

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; MELPHALAN; THIOTEPA;

ADULT; ADVANCED CANCER; ARTICLE; AUTOTRANSPLANTATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; STEM CELL TRANSPLANTATION;

EID: 0031766638     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701398     Document Type: Article

References (32)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1997. Ca Cancer J Clin 1997; 47: 5-27.
2. Wingo PA, Tong T, Bolder S. Cancer Statistics, 1995. Ca Cancer J Clin 1995; 45: 8-20.
3. Thigpen JT, Blessing JA, Vance RB, Lambuth BW. Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 1989; 16: 58-65.
4. Quazi F, McGuire WP. The treatment of epithelial ovarian cancer. Cancer J Clin 1995; 45: 88-101.
5. Lotz JP, Machover D, Malassagne B et al. Tandem high-dose (HD) chemotherapy with VM-26, ifosfamide (IFM) and carboplatinum (CBDCA) with autologous bone marrow transplantation (ABMT) for patients with stage IIIc-IV ovarian cancer. Proc Am Soc Clin Oncol 1993; 12: 257 (Abstr.).
6. Mulder PO, Willemse B, Aalders JG et al. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 1989; 25: 645-649.
7. Dauplat J, Legras M, Condat P et al. High-dose melphalan and autologous bone marrow support for the treatment of ovarian carcinoma with positive second-look operation. Gynecol Oncol 1989; 34: 294-298.
8. Mulder PO, Sleijfer DT, Willemese PH et al. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplant for refractory solid tumors. Cancer Res 1989; 49: 4654-4658.
9. Viens P. Maraninchi D. High-dose chemotherapy and autologous marrow transplantation for common epithelial ovarian cancer. In: Armitage JO, Antman KH (eds). High-Dose Cancer Therapy, Williams and Walkins: Baltimore, 1992, pp 729-734.
10. Stiff P, McKenzie RS, Alberts DS et al. Bone marrow translantation for ovarian carcinoma in the United States: a survey of active programs. In: Dicke KA, Keating A (eds). Proc Sixth International ABMT Symposium. Cancer Treatment Research Education Fund: Arlington, 1993, pp 192-225.
11. Stiff P, Bayer R, Camarda M et al. A phase II trial of high dose mitoxantrone, carboplatin and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: an analysis of risk factor for clinical out- come. Gynecol Oncol 1995; 57: 278-285.
12. Shpall EJ, Clarke-Pearson D, Soper JT et al. High-dose alkylating agents chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 1990; 38: 386-391.
13. Benedetti-Panici P, Greggi S, Scambia G et al. High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 1995; 27: 133-138.
14. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-1317.
15. Corringham R, Gilmore M, Prentice H et al. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumor. Cancer 1993; 52: 1783-1787.
16. Marinchi D, Piana L, Blauner D et al. Phase I-II studies of high-dose alkylating agents in poor risk patients. In: Dicke K, Spitzer T, Jaggenth S (eds). ABMT: Proc Third International Symposium. University of Texas MD Anderson Hospital: Houston, 1987, pp 475-480.
17. Knight WA, Page CP, Kuhn JG et al. High-dose L-PAM and autologous marrow infusion for refractory solid tumors. Proc Am Soc Clin Oncol 1994; 3: 150 (Abstr.).
18. Lazarus HM, Reed MD, Spitzer TR et al. High-dose intravenous thiotepa and cryopreserved autologous bone marrow transplant for therapy of refractory cancer. Cancer Treat Rep 1987; 71: 689-695.
19. Demirer T, Buckner CD, Appelbaum FR et al. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996; 17: 769-774.
20. Weaver CH, Bensinger WI, Appelbaum F et al. Phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
21. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support inpatients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.
22. Shuhart MC, McDonald GB. Gastrointestinal and hepatic complications, in Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, pp 454-481.
23. Crawford SW. Critical care and respiratory failure. In: Thomas ED, Forman SJ, Blume K (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, pp 513-526.
24. Bensinger WI, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158-3163.
25. Rowley SD, Bensinger WI, Gooley TA et al. The effect of cell concentration on bone marrow and peripheral blood stem cells cryopreservation. Blood 1994; 83: 2731-2736.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-488.
27. Pepe MS, Longton G, Pettinger M et al. Summarizing data on survival, relapse and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol 1993; 83: 602-607.
28. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-1308.
29. Menichella G, Pierelli L, Foddai ML et al. Autologous blood stem cell harvest and transplantation in patients with advanced ovarian cancer. Br J Haematol 1991; 79: 444-450.
30. Viens P, Maraninchi D, Giacchetti S et al. High-dose mel- phalan and autologous marrow rescue in advanced epithelial carcinoma: a retrospective analysis of 35 patients with advanced ovarian adenocarcinoma treated in France. Bone Marrow Transplant 1990; 5: 227-233.
31. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin vs paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 1996; 334: 1-6.
32. Ozols RF. Treatment of ovarian cancer: current status. Semin Oncol 1994; 21: 1-9.